Continuing Education Activity

Menopause is characterized by the complete absence of menstrual cycles, which occurs when a female has no ovarian follicles left in reserve and is clinically diagnosed when a woman has had amenorrhea for 1 year. In the United States, the average age of menopause is 51. This course reviews bleeding after menopause has been established, termed postmenopausal bleeding (PMB), which is abnormal and is the reason for approximately two-thirds of all gynecologic office visits in postmenopausal women as well as underlying etiologies. Though the most common cause of PMB is atrophy of the lower reproductive tract, 90% of postmenopausal women diagnosed with endometrial cancer presented with vaginal bleeding. Participants will also gain an understanding of the importance of early diagnosis and management, which are essential for a significantly more favorable prognosis, endometrial cancer risk factors, and management based on the identified etiology. This activity for healthcare professionals aims to enhance learners' competence in selecting appropriate diagnostic tests, initiating individualized management, and fostering effective interprofessional teamwork to improve outcomes for patients with postmenopausal bleeding.

Objectives:

• Identify the various etiologies of postmenopausal bleeding.
• Differentiate the differential diagnoses of postmenopausal bleeding.
• Implement the recommended management of postmenopausal bleeding.
• Apply interprofessional team strategies to improve care coordination and outcomes for patients with postmenopausal bleeding.

Access free multiple choice questions on this topic.

Introduction

Menopause is characterized by the complete absence of menstrual cycles, which occurs when a female has no ovarian follicles left in reserve and is clinically diagnosed when a woman has had amenorrhea for 1 year. In the United States, the average age of menopause is 51.[1] Bleeding after menopause has been established, termed postmenopausal bleeding (PMB), is considered abnormal and is the reason for approximately two-thirds of all gynecologic office visits in postmenopausal women.[2][3]

The differential diagnoses associated with PMB include several conditions. Though the most common cause of PMB is atrophy of the lower reproductive tract, 90% of postmenopausal women diagnosed with endometrial cancer presented with vaginal bleeding.[4][5] As with most malignancies, early diagnosis and management lead to a significantly more favorable prognosis.[6] Therefore, any postmenopausal woman with vaginal bleeding should be promptly and appropriately evaluated through a comprehensive clinical examination and diagnostic studies, including endometrial biopsy and imaging. Typically, management depends on the etiology identified. Due to the frequency with which clinicians encounter PMB, healthcare professionals should have enhanced knowledge in selecting appropriate diagnostic tests, managing the etiology, and fostering effective interprofessional teamwork to improve outcomes in patients with this common condition.

Etiology

PMB is often attributed to the uterus, with women mistakenly attributing bleeding to menstrual bleeding despite not having had menses for over 1 year. However, the bleeding may also arise from the urethra, vulva, vagina, cervix, or rectum. The most common cause of PMB is genitourinary atrophy, accounting for 60%.[7] The etiology of PMB may also be nongynecologic (eg, the urethra, bladder, or GI tract) and mistaken for vaginal bleeding.[1] Some common underlying causes of PMB include: 

• Vaginal or endometrial atrophy
• Urogenital infections (eg, endometrial tuberculosis, vaginitis, cystitis, or cervicitis)
• Medications (eg, estrogen, tamoxifen, and anticoagulants)
• Uterine leiomyomas
• Genital tract malignancies
• Vaginal foreign bodies
• Endometrial polyps
• Genitourinary atrophy
• Endometrial hyperplasia with or without atypia [1][8][4][5]

Epidemiology

Vaginal bleeding is reported in up to 10% of postmenopausal women and is the presenting symptom for approximately two-thirds of gynecologic office visits in this population.[9][2] However, the incidence of PMB may decrease with age. With the onset of menopause, bleeding is reported in approximately 40% of women per year, but 3 years after menopause, PMB decreases to 4% per year.[1] 

In the United States, the incidence of endometrial cancer has risen gradually, increasing by about 1% to 2% each year. By 2022, the annual rate of uterine cancer reached 28.8 cases per 100,000 women, up from 23.5 per 100,000 in 2000. Mortality has also trended upward, with an overall death rate of 5.3 per 100,000 women annually between 2019 and 2023, compared with 4.1 per 100,000 in 2000.[10]

Endometrial cancer is the fifth most common cause of death due to malignancy in the United States and the fourth most common overall cancer in females.[11] Furthermore, endometrial cancer is the most commonly diagnosed cancer in women and the most common site of uterine cancer, accounting for 92% of cases.[5][12] Over 90% of postmenopausal women with endometrial cancer present with PMB.[5] In women younger than 50, less than 1% of PMB is secondary to endometrial cancer. However, the incidence of PMB due to endometrial cancer increases to 24% in women older than 80.[13] The global incidence of endometrial cancer is increasing, primarily due to the increased prevalence of endometrial cancer risk factors (eg, obesity and late menopause). The number of patients diagnosed with endometrial cancer is anticipated to double by the year 2030.[2][14]

Pathophysiology

The most common etiology for PMB is an atrophic endometrium. The hypoestrogenic environment following menopause leads to genitourinary atrophy. The collapsed and atrophic endometrial lining within the uterus contains scant or no fluid to prevent friction within the cavity, leading to epithelial microerosions and subsequent chronic inflammation. Chronic endometritis secondary to atrophy can present with vaginal spotting or light bleeding. Pelvic ultrasounds performed in these patients typically reveal a thin endometrial stripe with an otherwise normal appearance, a small uterus, and small ovaries.[15]

Conversely, unopposed estrogen exposure often develops premalignant or malignant endometrial conditions. Systemic estrogen-only therapy, obesity, and estrogen-secreting tumors can lead to abnormal endometrial changes. Some women have genetic predispositions to endometrial cancer, eg, Lynch syndrome and Cowden disease.[12] More recent studies demonstrate that BRCA gene mutation carriers may have a slightly increased risk of endometrial cancer, especially those with a BRCA1 mutation.[16]

Histopathology

Postmenopausal Endometrial Histologic Findings

The hypoestrogenic environment has several effects on the postmenopausal endometrium that are apparent on microscopic examination. Normal premenopausal proliferative endometrium contains regularly spaced, ordered glands lined by simple epithelial cells within the stroma with an approximate 1 to 1 gland-to-stroma ratio. Furthermore, histologically, mitotic activity is a characteristic feature of proliferative endometrium. Conversely, normal histologic findings in the postmenopausal endometrium show widely spaced glands that vary from small to cystically dilated. Moreover, the mitotic proliferative activity characteristic of a premenopausal endometrium is not apparent in postmenopausal endometrial cells.[8][4] Pathologic endometrial findings have varying histologic features depending on the underlying etiology. For instance, the histopathology of endometrial polyps frequently shows cellular immaturity with cystic hyperplasia, while smooth muscle fibers are a characteristic finding of uterine fibroids. Both conditions have a higher risk of malignant transformation in postmenopausal women.[17][18] In women with PMB, the most concerning abnormal histologic findings are endometrial hyperplasia and carcinoma.

Endometrial Hyperplasia Histologic Findings

Characteristic histologic findings of endometrial hyperplasia include widespread crowding of endometrial glands, a disordered proliferation of glands, and an increased gland-to-stroma ratio. The precise ratio diagnostic of endometrial hyperplasia is debated; however, many pathologists use a gland-to-stroma ratio of 2 to 1.[4] In benign endometrial hyperplasia, glandular cytology is normal, with only occasional mitotic figures noted. However, on histological examination, gland crowding and abnormal gland nuclei are typically seen in endometrial intraepithelial neoplasia (EIN), considered a premalignant condition.[8][4] 

Endometrial Cancer Histologic Findings

One of the most concerning etiologies of PMB is endometrial cancer, which is typically subclassified into type I or II based on histologic morphology, grade, and hormone receptors.[14][19] The following histologic findings are associated with each enodmetial cancer type:

• Endometrial carcinoma type 1: The most common histologic type of endometrial carcinoma, accounting for up to 90% of uterine cancers, is primarily composed of grade I or II endometrioid adenocarcinomas, which involve the endometrial glands. Histologically, solid areas, maze-like glands, or appreciable cribriforming are observed. Most of these endometrioid adenocarcinomas are low-grade and confined to the uterus.[11]

• Endometrial carcinoma type 2: These are rare, high-grade, poorly differentiated, and more aggressive types of uterine cancers that include clear cell carcinoma, sarcoma, carcinosarcoma, and papillary serous histologies. Type 2 endometrial cancers have a higher risk of extrauterine disease at diagnosis and a worse prognosis than type I tumors. For instance, though only 10% of uterine cancers are papillary serous, they cause approximately 40% of deaths.[11]

History and Physical

A comprehensive history is essential when evaluating PMB to assess both underlying etiologies and establish the patient's menopausal status. Excluding a malignant etiology, primarily endometrial cancer, is the most critical aspect of PMB evaluation.[14] Clinicians should elicit a thorough history, including the following standard elements:

History of Present Illness

To evaluate the differential diagnoses for PMB and clinically confirm the patient's menopausal state, clinicians should obtain a history regarding the nature of the patient's current bleeding and any associated symptoms. Heavy menstrual bleeding or other abnormal uterine bleeding patterns may indicate structural abnormalities (eg, leiomyomas, polyps), hyperplasia, or malignancy.[20] PMB onset, duration, heaviness, and precipitating factors (eg, bleeding after intercourse or after wiping) are all essential to characterize vaginal bleeding symptoms.[14] Associated symptoms, including fever, pelvic pain, dysuria, vasomotor symptoms, dyspareunia, and vaginal dryness, should also be investigated.[21][22]

• Past medical history: Potential etiologies for abnormal bleeding include obesity, polycystic ovarian syndrome, diabetes, thyroid disease, pelvic infection, or coagulopathies. Several of these conditions are also risk factors for endometrial cancer or hyperplasia (eg, obesity and diabetes). Radiation exposure may also cause PMB.[23][14] 
• Gynecologic history: Primarily, a thorough review of the menstrual history, including the last menstrual period, is critical when assessing an individual's postmenopausal status. Menarche younger than 12 years (ie, early menarche) or menopause beginning in patients older than 55 (ie, late menopause) increases the risk for endometrial cancer.[13] Additionally, recent Pap and HPV testing may indicate cervical or endometrial etiologies.[20]
• Surgical history: Past surgical procedures can provide clinicians with potential etiologies for vaginal bleeding and menopausal amenorrhea. Recent pelvic procedures can result in postoperative bleeding, and surgically induced menopause (eg, hysterectomy, oophorectomy) can assist in definitively establishing a patient's menopausal status.[20]
• Social history: Genitourinary infections, such as sexually transmitted diseases, are also causes of PMB. Additionally, individuals who smoke have an increased risk of bladder cancer, mesh erosion, and hematuria, which may cause bleeding.[9][24] 
• Family history: Due to the increased malignancy risk, a family history of breast, gynecologic, urologic, or gastrointestinal cancers should be assessed, as well as inherited mutations (eg, Lynch or Cowden syndrome) that can predispose individuals to endometrial cancer.[14]
• Medications: Clinicians should also elicit medication history from patients, as hormone replacement therapy, tamoxifen, anticoagulants, and certain herbal supplements can all affect the endometrial lining, leading to PMB.[25][26][27] 

Physical Exam

On physical exam, it is crucial to thoroughly evaluate the internal and external anatomy of the genital tract. A speculum exam should be performed to visualize bleeding sites, genital lesions, lacerations, urethral prolapse, and signs of genitourinary atrophy, which typically include pale, dry vaginal epithelium with loss of rugae. Erythema, petechiae, friability, and discharge may indicate inflammation. Furthermore, clinicians can palpate for pelvic masses, abdominal distention, and enlarged lymph nodes through a bimanual exam.[14][21][6]

Evaluation

Diagnostic Studies

In addition to the clinical assessment, diagnostic evaluation of PMB is primarily directed toward excluding endometrial hyperplasia or malignancy. In April 2026, the American College of Obstetricians and Gynecologists (ACOG) published a new guideline on the use of endometrial biopsy and transvaginal ultrasound for the evaluation of PMB. This Clinical Practice Update revises prior recommendations in light of the increasing incidence of endometrial cancer, along with newer evidence regarding tumor subtypes, associated risk factors, and ongoing challenges in delivering gynecologic care. For most patients presenting with postmenopausal bleeding, initial evaluation should include both transvaginal ultrasonography and endometrial sampling.[10]

Only in very carefully selected cases, transvaginal ultrasound alone may be appropriate at the outset. This applies to patients with a single episode of PMB, a clearly visualized endometrium measuring 4 mm or less, no significant risk factors for endometrial cancer, and reliable access to timely follow-up. However, these patients should be counseled that any persistent or recurrent bleeding warrants prompt reevaluation.[10]

Factors associated with a higher risk of endometrial cancer include:

• Use of exogenous estrogen (eg, supplements or hormone therapy, with or without progestin)
• Use of selective estrogen receptor modulators (eg, tamoxifen)
• Body mass index greater than 30 kg/m²
• Nulliparity
• Known or suspected hereditary cancer syndromes (eg, Lynch or Cowden syndrome) or a family history of endometrial cancer
• Black race, which is independently associated with higher rates of aggressive endometrial cancer subtypes
• Diabetes mellitus

Several other factors may also be associated with a higher risk of endometrial cancer. Therefore, patients who experience unscheduled bleeding more than 6 months after starting hormone therapy should undergo further evaluation.[10] Laboratory studies may be considered to assess for complications secondary to heavy vaginal bleeding and to help exclude differential diagnoses.[6]

Endometrial Biopsy

Endometrial sampling is a first-line test for evaluating PMB in any patient because this study provides tissue for histologic diagnosis, which is critical for identifying malignancies. Other indications for endometrial sampling in patients with PMB include:[5]

• Persistent or recurrent bleeding PMB, despite a thin endometrial stripe on ultrasound
• Risk factors for endometrial cancer (eg, obesity, smoking, exposure to unopposed estrogen)
• Endometrial lining thickness by transvaginal ultrasound of >4 mm in a woman with PMB
• Inadequate visualization of the endometrium in imaging studies [5]

ACOG also recommends performing endometrial sampling on women with abnormal uterine bleeding older than 45.[23] The primary modalities utilized for endometrial sampling include dilation and curettage (D&C) and outpatient disposable thin plastic devices inserted through the endocervical opening into the endometrial cavity without anesthesia.[28][29] Clinicians have performed D&Cs with or without hysteroscopy for years for histologic assessment, as the diagnostic sensitivity for endometrial cancer exceeds 90%.[30][31] In studies, office endometrial biopsy using flexible plastic samplers has been found to have similar diagnostic accuracy.[32][33][34] However, endometrial biopsy can result in findings that are insufficient for diagnosis, with rates of sampling failure up to 54%.[5] The diagnostic accuracy of endometrial sampling correlates positively with the amount of tissue that is collected.[35] Please see StatPearls' companion resource, "Endometrial Biopsy," for further information.

Imaging Studies

The technique ACOG recommends for measuring endometrial thickness is to use the thickest portion of the endometrial stripe seen on a long-axis uterine view, measured from anterior to posterior.[5] Before April 2026, an endometrial stripe thickness of 4 mm or less was thought to have a negative predictive value of greater than 99% for endometrial carcinoma.[36] The probability of having endometrial cancer with an endometrial stripe thickness of less than 4 mm was thought to be approximately 0.3%.[5] However, reevaluation of prior triage strategies has been driven by several concerns. The reliability of transvaginal ultrasonography to exclude endometrial cancer depends on disease prevalence, and its negative predictive value declines as incidence rises, which has occurred steadily in the United States. More recent data also suggest lower-than-expected sensitivity of ultrasound using a 4-mm endometrial thickness cutoff, raising the possibility that a meaningful proportion of cancers may be missed.[10]

At the same time, endometrial cancer incidence and mortality have increased disproportionately among Black women, reflecting broader care inequities and social determinants of health rather than inherent biological differences. Higher rates of aggressive tumor subtypes in this population, along with reduced sensitivity of ultrasound for detecting these cancers, further limit the effectiveness of ultrasound-based triage.[10]

Technical limitations also affect ultrasonography, as adequate visualization of the endometrium is not always achievable, particularly in patients with conditions, eg, fibroids or adenomyosis. In addition, reliance on follow-up for “persistent” or “recurrent” bleeding is problematic due to unclear definitions and barriers to timely reevaluation, which can delay diagnosis and worsen outcomes. Together, these factors highlight important limitations of ultrasound-only approaches and support a lower threshold for endometrial sampling in patients with PMB.[10]

A thickened endometrial stripe may be caused by hyperplasia, malignancy, and intracavitary lesions (eg, leiomyomas and endometrial polyps). For ultrasound findings suggestive of intracavitary lesions or a history-based suspicion (eg, previous polyps), additional imaging may be useful, including saline-infused ultrasonography or a hysterosalpingogram. Pelvic computed tomography (CT) and magnetic resonance imaging (MRI) are sometimes used to better characterize urogenital pathology noted on ultrasound.[4] However, hysteroscopy with dilation and curettage is the gold standard as diagnostic sampling and therapeutic excision for some etiologies of PMB (eg, endometrial polyps) can be performed simultaneously. Furthermore, blind endometrial sampling without hysteroscopy may miss focal lesions or intrauterine pathology (eg, polyps), and mass lesions may deflect flexible disposable devices. Consequently, further imaging evaluation should be considered for patients with insufficient sampling or persistent vaginal bleeding in whom focal lesions may have been missed; hysteroscopy with dilation and curettage or directed biopsy may be warranted.[5][19]

Laboratory Studies

A CBC, TSH, and coagulation studies (eg, prothrombin time and partial thromboplastin time) should be considered in individuals with PMB to help exclude certain differential diagnoses and to assess for secondary anemia due to abnormal bleeding.[6] Vaginal cultures for sexually transmitted diseases and other genital infections should be considered if clinically indicated. In women who have undergone early menopause (ie, older than 40), a pregnancy test is also typically performed.[23] Papanicolaou smears are not diagnostic but can suggest PMB etiologies (eg, cervicitis, sexually transmitted diseases, cervical and endometrial cancers).[6]

Treatment / Management

The underlying cause primarily directs the treatment of PMB. However, other clinical factors, including patient comorbidities and preferences, as well as PMB characteristics (eg, heaviness and duration), are considered when determining management.[4][21][37]

Genitourinary Atrophy

Bleeding is usually self-limited and requires no treatment. Vaginal dryness may be treated with nonhormonal vaginal moisturizers and lubricants to maintain sexual activity. Vulvar and vaginal atrophy symptoms can be effectively reversed by topical estrogen and are the preferred pharmacologic therapy for genitourinary atrophy. Oral hormone replacement and hormonal receptor modulators (eg, ospemifene) also may be considered if no improvement is noted with other treatments.[21]

Endometrial Polyps

Approximately 30% of PMB cases are caused by endometrial polyps; however, polyps can be asymptomatic. Furthermore, the severity of PMB is not affected by the number or size of polyps. A reported 1% of all endometrial polyps are malignant, most commonly occurring in postmenopausal women.[17] Therefore, endometrial polyps in symptomatic postmenopausal women should be removed and histologically assessed. Surgical excision should be considered in asymptomatic women at higher risk of malignancy (eg, large polyps, tamoxifen use, obesity, or diabetes).[38] Hysteroscopic polypectomy is the preferred treatment because the clinician can obtain targeted biopsies and excise polyps simultaneously.[17]

Uterine Leiomyoma

Typically, leiomyomas (ie, fibroids) are benign and regress during menopause and may not need treatment if patients are asymptomatic. A small percentage of fibroids are malignant, primarily in postmenopausal women. Occasionally, benign leiomyomas may grow or become symptomatic even in postmenopausal patients, particularly in obese women, due to peripheral conversion of estrogen from adipose stores.[39] 

In women with PMB found to have uterine fibroids with an otherwise normal evaluation, pharmacologic (eg, aromatase inhibitors and selective estrogen receptor modulators) or surgical (eg, myomectomy and hysterectomy) therapy may be considered. However, leiomyosarcomas can not be definitively excluded through laboratory or imaging studies, and symptomatic postmenopausal women are at higher risk; therefore, clinicians should thoroughly counsel patients and determine management through shared decision-making.[39][40]

Genitourinary Infection

For sexually transmitted diseases and other genital infections, treatment is guided by vaginal culture results.[23][6] Clinicians may consider oral doxycycline to treat endometritis.[41]

Cervical, Vaginal, and Vulvar Carcinomas

Most treatment modalities for these PMB etiologies include surgery and chemoradiotherapy based on the stage.[42][43]

Endometrial Hyperplasia or Malignancy

Endometrial hyperplasia is classified as benign endometrial hyperplasia or intraepithelial neoplasia. Management of hyperplasia includes surgical and nonsurgical therapies; the treatment approach is individualized based on clinical factors (eg, comorbid conditions). Please see StatPearls' companion resources, "Endometrial Hyperplasia" and "Premalignant Lesions of the Endometrium," for further information. However, endometrial carcinoma requires surgical treatment and staging by gynecologic oncology specialists. Additionally, chemotherapy and radiation may be indicated for some patients.[19][4]

Benign endometrial hyperplasia

Also referred to as nonatypical endometrial hyperplasia, this benign type of hyperplasia is typically managed with hormonal therapy and/or curettage.[4] 

Endometrial intraepithelial neoplasia

The approach to treatment depends on various clinical factors, including patient preferences. Please see StatPearls' companion resource, "Premalignant Lesions of the Endometrium," for further information. Generally, in postmenopausal women, fertility conservation is not desired; therefore, minimally invasive hysterectomy with bilateral salpingectomy is the preferred treatment. Shared decision-making should be utilized when determining if bilateral oophorectomy is also performed.[4] 

Medical management is an option for patients who are declining surgery or are poor surgical candidates. Patients should be cautioned that many women with EIN have concurrent endometrial malignancy. If medical treatment is chosen, repeat endometrial sampling to assess therapeutic response should be performed at 3 to 6 months, with a minimum of 1 year. Nonsurgical therapies include:[4]

• Megestrol 80 mg orally twice a day
• Depot medroxyprogesterone acetate 150 mg intramuscularly every 3 months
• Micronized vaginal progesterone 100 to 200 mg daily
• Levonorgestrel intrauterine device, 52 mg
• Medroxyprogesterone acetate orally 10 to 20 mg daily [4]

Endometrial adenocarcinoma

Definitive treatment with hysterectomy and comprehensive staging is the standard of care. Prognosis and appropriate adjuvant therapy are determined by staging.[12][4]

Hematuria 

Genitourinary atrophy can lead to asymptomatic microscopic hematuria. Because the risk of urinary malignancy is lower in women without risk factors (eg, smokers, no gross hematuria) than in men, ACOG only recommends evaluation in asymptomatic low-risk women if urine microscopy shows more than 25 red blood cells per high-power field. Clinical findings and diagnostic studies consistent with acute cystitis should be treated with appropriate antibiotics.[44]

Gastrointestinal Bleeding

The differential diagnoses for PMB include gastrointestinal etiologies (eg, hemorrhoids and diverticulitis), which can be mistaken for vaginal bleeding. Management may consist of surgery, anti-inflammatories, or antibiotics. Recurrent or severe bleeding may necessitate referral to a gastrointestinal specialist for additional evaluation and treatment.[45]

Medications

Postmenopausal hormone replacement therapy frequently causes PMB for the first 2 to 3 months after initiation, which spontaneously resolves in most women. However, clinicians should evaluate for endometrial pathology in women with persistent or recurrent PMB following the first few months of therapy. For anticoagulants leading to vaginal bleeding, progestin therapy may improve bleeding until anticoagulants can be discontinued. Longer-term solutions may need to be discussed with patients on lifelong anticoagulation.[3]

Differential Diagnosis

Clinicians evaluating patients with PMB must consider differential diagnoses with presentations similar to PMB, which may arise from nongynecologic (eg, the urethra, bladder, or GI tract) or gynecologic sites.[1] Common conditions that should also be considered when evaluating PMB include:

• Urogenital infections (eg, endometritis, vaginitis, cystitis, or cervicitis) [46]
• Uterine leiomyomas
• Genital tract malignancies
• Vaginal foreign bodies
• Gastrointestinal conditions (eg, diverticulitis, colitis, hemorrhoids, malignancy)
• Genitourinary atrophy
• Radiation effects on adjacent organs (eg, hemorrhagic cystitis, proctitis, necrosis) [47][1][8][4][5][47]

Prognosis

PMB has a favorable prognosis, as the most common etiologies are benign and treatable. Furthermore, the prognosis for the most common malignant PMB etiology, endometrial cancer, is significantly better than that of other cancers, with a 5-year survival rate of 90%.[12] In patients diagnosed with endometrial hyperplasia who underwent hysterectomy, approximately 43% had undiagnosed concurrent endometrial carcinoma.[4]

Complications

The primary complication of PMB is secondary anemia, which occurs in approximately 10% of postmenopausal women.[48] Other complications that may occur are typically associated with the underlying etiology. For instance, genitourinary atrophy can decrease quality of life due to reduced sexual intimacy and self-esteem, while uterine fibroids may cause pelvic discomfort.[49][39] Management of PMB etiologies, eg, pharmacologic therapy of endometrial hyperplasia with megestrol, can also be associated with adverse effects, including weight gain, nausea, venous thromboembolism, and continued vaginal bleeding.[4]

Consultations

Gynecologists are frequently consulted to evaluate and manage patients with PMB. Urologists or urogynecologists may also be helpful if a urologic etiology is suspected. Consultation with a gynecologic oncologist should be obtained for patients with a gynecologic malignancy, as the prognosis is better for patients cared for by gynecologic oncologists.[49]

Deterrence and Patient Education

Clinicians should provide perimenopausal patients with anticipatory education regarding menopausal transition and typical changes that may occur during menstrual cycles. Patients should be educated that any bleeding after menopause is established is considered abnormal. Patients should be instructed when to seek medical attention and asked about abnormal vaginal bleeding during routine office visits. Because primary care clinicians are often the first to evaluate patients with PMP, they should educate patients on addressing endometrial hyperplasia risk factors (eg, obesity, unopposed estrogen exposure). Furthermore, preventive therapies, including intrauterine devices, have been shown to decrease the rate of uterine cancer by 50%.[4] 

Enhancing Healthcare Team Outcomes

PMB presents a diagnostic challenge due to its diverse etiologies, requiring a comprehensive and collaborative approach by an interprofessional team to ensure patient-centered care. Physicians, advanced practitioners, nurses, pharmacists, radiologists, and pathologists each play a critical role in evaluating and managing this condition. Radiology and pathology specialists collaborate closely with primary care clinicians, gynecologists, and other ancillary team members to accurately identify the underlying cause and develop a tailored treatment plan.

Effective interprofessional communication and shared decision-making are pivotal in aligning the team’s efforts, improving outcomes, and enhancing patient satisfaction. By fostering a holistic and integrated care approach, the team ensures not only the identification and treatment of the condition but also the provision of support and safety throughout the patient journey. For premalignant gynecologic conditions, timely consultation with gynecologic oncologists is crucial to optimizing care and improving clinical outcomes. This level of coordination highlights the importance of mutual respect, clear communication, and shared responsibilities among healthcare professionals to deliver exceptional care that prioritizes patient safety, enhances outcomes, and strengthens team performance.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Carugno J. Clinical management of vaginal bleeding in postmenopausal women. Climacteric. 2020 Aug;23(4):343-349. [PubMed: 32233689]

2.

Clarke MA, Long BJ, Del Mar Morillo A, Arbyn M, Bakkum-Gamez JN, Wentzensen N. Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018 Sep 01;178(9):1210-1222. [PMC free article: PMC6142981] [PubMed: 30083701]

3.

Santoro N, Roeca C, Peters BA, Neal-Perry G. The Menopause Transition: Signs, Symptoms, and Management Options. J Clin Endocrinol Metab. 2021 Jan 01;106(1):1-15. [PubMed: 33095879]

4.

Ring KL, Mills AM, Modesitt SC. Endometrial Hyperplasia. Obstet Gynecol. 2022 Dec 01;140(6):1061-1075. [PubMed: 36357974]

5.

ACOG Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol. 2018 May;131(5):e124-e129. [PubMed: 29683909]

6.

Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and Management of Endometrial Cancer. Am Fam Physician. 2016 Mar 15;93(6):468-74. [PubMed: 26977831]

7.

Smith PP, O'Connor S, Gupta J, Clark TJ. Recurrent postmenopausal bleeding: a prospective cohort study. J Minim Invasive Gynecol. 2014 Sep-Oct;21(5):799-803. [PubMed: 24681065]

8.

Swain M, Kulkarni AD. Endometrium at Menopause: The Pathologist's View. J Midlife Health. 2021 Oct-Dec;12(4):310-315. [PMC free article: PMC8849152] [PubMed: 35264839]

9.

Jo HC, Baek JC, Park JE, Park JK, Cho IA, Choi WJ, Sung JH. Clinicopathologic Characteristics and Causes of Postmenopausal Bleeding in Older Patients. Ann Geriatr Med Res. 2018 Dec;22(4):189-193. [PMC free article: PMC7387628] [PubMed: 32743272]

10.

Updated Guidance Regarding The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Individuals With Postmenopausal Bleeding. Obstet Gynecol. 2026 Jul 01;148(1):e87-e91. [PubMed: 41990335]

11.

Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019 Jul;69(4):258-279. [PubMed: 31074865]

12.

Practice Bulletin No. 149: Endometrial cancer. Obstet Gynecol. 2015 Apr;125(4):1006-1026. [PubMed: 25798986]

13.

Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022 Apr 09;399(10333):1412-1428. [PubMed: 35397864]

14.

Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, Oaknin A. Endometrial cancer. Nat Rev Dis Primers. 2021 Dec 09;7(1):88. [PMC free article: PMC9421940] [PubMed: 34887451]

15.

Ferenczy A. Pathophysiology of endometrial bleeding. Maturitas. 2003 May 30;45(1):1-14. [PubMed: 12753939]

16.

Matanes E, Volodarsky-Perel A, Eisenberg N, Rottenstreich M, Yasmeen A, Mitric C, Lau S, Salvador S, Gotlieb WH, Kogan L. Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2021 May;28(5):947-956. [PubMed: 33249269]

17.

Nijkang NP, Anderson L, Markham R, Manconi F. Endometrial polyps: Pathogenesis, sequelae and treatment. SAGE Open Med. 2019;7:2050312119848247. [PMC free article: PMC6501471] [PubMed: 31105939]

18.

Wen KC, Horng HC, Wang PH, Chen YJ, Yen MS, Ng HT., Taiwan Association of Gynecology Systematic Review Group. Uterine sarcoma Part I-Uterine leiomyosarcoma: The Topic Advisory Group systematic review. Taiwan J Obstet Gynecol. 2016 Aug;55(4):463-71. [PubMed: 27590365]

19.

Parkash V, Fadare O, Tornos C, McCluggage WG. Committee Opinion No. 631: Endometrial Intraepithelial Neoplasia. Obstet Gynecol. 2015 Oct;126(4):897. [PubMed: 26393443]

20.

Klein DA, Paradise SL, Reeder RM. Amenorrhea: A Systematic Approach to Diagnosis and Management. Am Fam Physician. 2019 Jul 01;100(1):39-48. [PubMed: 31259490]

21.

Nappi RE, Martini E, Cucinella L, Martella S, Tiranini L, Inzoli A, Brambilla E, Bosoni D, Cassani C, Gardella B. Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women. Front Endocrinol (Lausanne). 2019;10:561. [PMC free article: PMC6712495] [PubMed: 31496993]

22.

Gibson CJ, Huang AJ, McCaw B, Subak LL, Thom DH, Van Den Eeden SK. Associations of Intimate Partner Violence, Sexual Assault, and Posttraumatic Stress Disorder With Menopause Symptoms Among Midlife and Older Women. JAMA Intern Med. 2019 Jan 01;179(1):80-87. [PMC free article: PMC6583410] [PubMed: 30453319]

23.

Committee on Practice Bulletins—Gynecology. Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol. 2012 Jul;120(1):197-206. [PubMed: 22914421]

24.

Jubber I, Ong S, Bukavina L, Black PC, Compérat E, Kamat AM, Kiemeney L, Lawrentschuk N, Lerner SP, Meeks JJ, Moch H, Necchi A, Panebianco V, Sridhar SS, Znaor A, Catto JWF, Cumberbatch MG. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. Eur Urol. 2023 Aug;84(2):176-190. [PubMed: 37198015]

25.

van Hunsel FP, Kampschöer P. [Postmenopausal bleeding and dietary supplements: a possible causal relationship with hop- and soy-containing preparations]. Ned Tijdschr Geneeskd. 2012;156(41):A5095. [PubMed: 23062258]

26.

Chandrareddy A, Muneyyirci-Delale O, McFarlane SI, Murad OM. Adverse effects of phytoestrogens on reproductive health: a report of three cases. Complement Ther Clin Pract. 2008 May;14(2):132-5. [PubMed: 18396257]

27.

Unfer V, Casini ML, Costabile L, Mignosa M, Gerli S, Di Renzo GC. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2004 Jul;82(1):145-8, quiz 265. [PubMed: 15237003]

28.

Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012 Aug;120(2 Pt 1):383-97. [PubMed: 22825101]

29.

Terzic MM, Aimagambetova G, Terzic S, Norton M, Bapayeva G, Garzon S. Current role of Pipelle endometrial sampling in early diagnosis of endometrial cancer. Transl Cancer Res. 2020 Dec;9(12):7716-7724. [PMC free article: PMC8798375] [PubMed: 35117374]

30.

Kaan M. [Arguments and counter-arguments about the orthodontic treatment of missing incisors. Literature review]. Fogorv Sz. 2010 Sep;103(3):83-8. [PubMed: 21058493]

31.

Sany O, Singh K, Jha S. Correlation between preoperative endometrial sampling and final endometrial cancer histology. Eur J Gynaecol Oncol. 2012;33(2):142-4. [PubMed: 22611951]

32.

Ferenczy A, Shore M, Guralnick M, Gelfand MM. The Kevorkian curette. An appraisal of its effectiveness in endometrial evaluation. Obstet Gynecol. 1979 Aug;54(2):262-7. [PubMed: 460766]

33.

Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000 Oct 15;89(8):1765-72. [PubMed: 11042572]

34.

Stovall TG, Ling FW, Morgan PL. A prospective, randomized comparison of the Pipelle endometrial sampling device with the Novak curette. Am J Obstet Gynecol. 1991 Nov;165(5 Pt 1):1287-90. [PubMed: 1957847]

35.

Reijnen C, Visser NCM, Bulten J, Massuger LFAG, van der Putten LJM, Pijnenborg JMA. Diagnostic accuracy of endometrial biopsy in relation to the amount of tissue. J Clin Pathol. 2017 Nov;70(11):941-946. [PubMed: 28389441]

36.

Manchanda R, Thapa S. An overview of the main intrauterine pathologies in the postmenopausal period. Climacteric. 2020 Aug;23(4):384-387. [PubMed: 32520598]

37.

Wouk N, Helton M. Abnormal Uterine Bleeding in Premenopausal Women. Am Fam Physician. 2019 Apr 01;99(7):435-443. [PubMed: 30932448]

38.

Sasaki LMP, Andrade KRC, Figueiredo ACMG, Wanderley MDS, Pereira MG. Factors Associated with Malignancy in Hysteroscopically Resected Endometrial Polyps: A Systematic Review and Meta-Analysis. J Minim Invasive Gynecol. 2018 Jul-Aug;25(5):777-785. [PubMed: 29454147]

39.

Ulin M, Ali M, Chaudhry ZT, Al-Hendy A, Yang Q. Uterine fibroids in menopause and perimenopause. Menopause. 2020 Feb;27(2):238-242. [PMC free article: PMC6994343] [PubMed: 31834160]

40.

Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B. Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database. Int J Gynecol Cancer. 2016 Jul;26(6):1098-104. [PubMed: 27177280]

41.

Di Caprio R, Lembo S, Di Costanzo L, Balato A, Monfrecola G. Anti-inflammatory properties of low and high doxycycline doses: an in vitro study. Mediators Inflamm. 2015;2015:329418. [PMC free article: PMC4421036] [PubMed: 25977597]

42.

Jhingran A. Updates in the treatment of vaginal cancer. Int J Gynecol Cancer. 2022 Mar;32(3):344-351. [PMC free article: PMC8921584] [PubMed: 35256422]

43.

Small W, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK. Cervical cancer: A global health crisis. Cancer. 2017 Jul 01;123(13):2404-2412. [PubMed: 28464289]

44.

Committee Opinion No.703: Asymptomatic Microscopic Hematuria in Women. Obstet Gynecol. 2017 Jun;129(6):e168-e172. [PubMed: 28368896]

45.

Dichman ML, Rosenstock SJ, Shabanzadeh DM. Antibiotics for uncomplicated diverticulitis. Cochrane Database Syst Rev. 2022 Jun 22;6(6):CD009092. [PMC free article: PMC9216234] [PubMed: 35731704]

46.

Cicinelli E, Resta L, Nicoletti R, Zappimbulso V, Tartagni M, Saliani N. Endometrial micropolyps at fluid hysteroscopy suggest the existence of chronic endometritis. Hum Reprod. 2005 May;20(5):1386-9. [PubMed: 15734762]

47.

Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol. 1998 Aug 01;148(3):234-40. [PubMed: 9690359]

48.

Nguyen PN, Nguyen VT. Assessment of paraclinical characteristics in peri- and postmenopausal bleeding women: is there a correlation between hemoglobin levels and ultrasonic indices? J Taibah Univ Med Sci. 2023 Jun;18(3):488-498. [PMC free article: PMC9906015] [PubMed: 36818167]

49.

Practice Bulletin No. 141: Management of Menopausal Symptoms: Correction. Obstet Gynecol. 2018 Mar;131(3):604. [PubMed: 29470333]

Disclosure: Sharon Sung declares no relevant financial relationships with ineligible companies.

Disclosure: Karen Carlson declares no relevant financial relationships with ineligible companies.